California Launches $50 Million, Fast-Track Stem Cell Drive
By David Jensen,
California Stem Cell Report
| 12. 11. 2014
Untitled Document
Directors of the $3 billion California stem cell agency today approved a $50 million plan that will radically reshape its efforts to produce a widely available stem cell treatment, a goal that it has not yet reached after 10 years of trying.
Speed is what the new push is all about – shortening the agency’s funding cycle for awards from nearly two years to about four months.
The plan was devised by
Randy Mills, who has been president since last May of the
California Institute for Regenerative Medicine (CIRM), as the agency is formally known. He has dubbed the effort
“CIRM 2.0” and says,
“We are in the business of trying to save people’s lives….We have to behave with the appropriate sense of urgency.”
CIRM 2.0 will begin next month for awards related to clinical trials with $50 million allotted for the first six months of the year. The program will be extended to other award programs as well. The agency hands out cash at an average rate of $190 million a year and has about...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Teddy Rosenbluth, The New York Times | 02.09.2026
Dr. Mehmet Oz has urged Americans to get vaccinated against measles, one of the strongest endorsements of the vaccine yet from a top health official in the Trump administration, which has repeatedly undermined confidence in vaccine safety.
Dr. Oz, the...
By Alex Polyakov, The Conversation | 02.09.2026
Prospective parents are being marketed genetic tests that claim to predict which IVF embryo will grow into the tallest, smartest or healthiest child.
But these tests cannot deliver what they promise. The benefits are likely minimal, while the risks to...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...